Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Bernardo Rapoport & Teresa Smit. (2017) Clinical pharmacology of neurokinin-1 receptor antagonists for the treatment of nausea and vomiting associated with chemotherapy. Expert Opinion on Drug Safety 16:6, pages 697-710.
Read now
Read now
Christina H Ruhlmann & Jørn Herrstedt. (2011) Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Expert Opinion on Drug Safety 10:3, pages 449-462.
Read now
Read now
Christina Ruhlmann & Jørn Herrstedt. (2010) Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting. Expert Review of Anticancer Therapy 10:2, pages 137-148.
Read now
Read now
Kamalesh K Sankhala, Devesh M Pandya, John Sarantopoulos, Scott A Soefje, Francis J Giles & Sant P Chawla. (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opinion on Drug Metabolism & Toxicology 5:12, pages 1607-1614.
Read now
Read now
Ian N Olver. (2008) Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Therapeutics and Clinical Risk Management 4:2, pages 501-506.
Read now
Read now
Simon JP Van Belle & Veronique Cocquyt. (2008) Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opinion on Pharmacotherapy 9:18, pages 3261-3270.
Read now
Read now
Rudolph M Navari. (2008) Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Review of Anticancer Therapy 8:11, pages 1733-1742.
Read now
Read now
Ian Olver, Suhas Shelukar & Karen C Thompson. (2007) Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. International Journal of Nanomedicine 2:1, pages 13-18.
Read now
Read now
Articles from other publishers (28)
Young-joo Lee. (2023) Online Versus In-Person Associational Involvement and Informal Volunteering. VOLUNTAS: International Journal of Voluntary and Nonprofit Organizations.
Crossref
Crossref
Priya Patel, J. Steven Leeder, Micheline Piquette-Miller & L. Lee Dupuis. (2017) Aprepitant and fosaprepitant drug interactions: a systematic review. British Journal of Clinical Pharmacology 83:10, pages 2148-2162.
Crossref
Crossref
Priya Patel, Paula D. Robinson, Jennifer Thackray, Jacqueline Flank, Mark T. Holdsworth, Paul Gibson, Andrea Orsey, Carol Portwine, Jason Freedman, Jennifer R. Madden, Robert Phillips, Lillian Sung & L. Lee Dupuis. (2017) Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatric Blood & Cancer 64:10, pages e26542.
Crossref
Crossref
P. Diemunsch & E. Noll. (2016) Nausee e vomiti postoperatori. EMC - Anestesia-Rianimazione 21:4, pages 1-14.
Crossref
Crossref
P. Diemunsch & E. Noll. (2016) Náuseas y vómitos postoperatorios. EMC - Anestesia-Reanimación 42:4, pages 1-15.
Crossref
Crossref
Chao Liu, Mei Hui, Peng Quan & Liang Fang. (2016) Drug in adhesive patch of palonosetron: Effect of pressure sensitive adhesive on drug skin permeation and in vitro-in vivo correlation. International Journal of Pharmaceutics 511:2, pages 1088-1097.
Crossref
Crossref
James J Natale, Tulla Spinelli, Selma Calcagnile, Corinna Lanzarotti, Giorgia Rossi, David CoxKimia Kashef. (2015) Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data. Journal of Oncology Pharmacy Practice 22:3, pages 485-495.
Crossref
Crossref
Delva Deauna-Limayo, Omar S Aljitawi, Siddhartha Ganguly, Sunil Abhyankar, Jo A Wick & Joseph P McGuirk. (2013) Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study. Journal of Oncology Pharmacy Practice 20:4, pages 263-269.
Crossref
Crossref
Selma Calcagnile, Corinna Lanzarotti, Giorgia Rossi, Anders Henriksson, Klaus Peter Kammerer & Wolfgang Timmer. (2013) Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Supportive Care in Cancer 21:10, pages 2879-2887.
Crossref
Crossref
Susan Sun, Joseph Schaller, Jiri Placek & Brett Duersch. (2013) Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemotherapy and Pharmacology 72:3, pages 509-513.
Crossref
Crossref
Pengfei Li, Ping Ma, Yan Wang, Weihang Tong, Jing Wang, Cheng Wu & Lihong Liu. (2012) Liquid chromatography–electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study. Journal of Chromatography B 895-896, pages 10-16.
Crossref
Crossref
Toshiaki Takahashi, Yukiko Nakamura, Asuka Tsuya, Haruyasu Murakami, Masahiro Endo & Nobuyuki Yamamoto. (2010) Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients. Cancer Chemotherapy and Pharmacology 68:3, pages 653-659.
Crossref
Crossref
Yuanyuan Wang, Yongqing Wang, Peipei Zhang, Zhihong Lu, Ying Gu & Ning Ou. (2011) Determination of palonosetron in human urine by LC–MS/MS. Bioanalysis 3:12, pages 1337-1342.
Crossref
Crossref
Tobias Engel Ayer Botrel, Otávio Augusto C. Clark, Luciana Clark, Luciano Paladini, Enéas Faleiros & Bruna Pegoretti. (2010) Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Supportive Care in Cancer 19:6, pages 823-832.
Crossref
Crossref
S. Aubrey Stoch, Cynthia Gargano, Jack Valentine, Matthew P. Braun, M. Gail Murphy, Margaret Fedgchin, Anup Majumdar, Edward Pequignot, Keith M. Gottesdiener, Kevin J. Petty, Deborah Panebianco, Dennis Dean, Walter K. Kraft & Howard E. Greenberg. (2010) Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemotherapy and Pharmacology 67:6, pages 1313-1321.
Crossref
Crossref
M.S. Aapro & C.M. Walko. (2010) Aprepitant: drug–drug interactions in perspective. Annals of Oncology 21:12, pages 2316-2323.
Crossref
Crossref
Lily P.H. Yang & Lesley J. Scott. (2009) Palonosetron. Drugs 69:16, pages 2257-2278.
Crossref
Crossref
Monique P. Curran & Dean M. Robinson. (2009) Aprepitant. Drugs 69:13, pages 1853-1878.
Crossref
Crossref
Laurel M. Adams, Brendan Johnson, Ke Zhang, Lin Yue, Lyndon C. Kirby, Peter Lebowitz & Randall Stoltz. (2009) Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Supportive Care in Cancer 17:9, pages 1187-1193.
Crossref
Crossref
Steven M. Grunberg, Matthew Dugan, Hyman Muss, Marie Wood, Susan Burdette-Radoux, Tracey Weisberg & Marisa Siebel. (2008) Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Supportive Care in Cancer 17:5, pages 589-594.
Crossref
Crossref
Margaret Pearson. 2010. Pediatric and Adolescent Osteosarcoma. Pediatric and Adolescent Osteosarcoma
385
394
.
Susumu Nakade, Tomoya Ohno, Junsaku Kitagawa, Yoshitaka Hashimoto, Masahiro Katayama, Hiroshi Awata, Yasuo Kodama & Yasuyuki Miyata. (2008) Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemotherapy and Pharmacology 63:1, pages 75-83.
Crossref
Crossref
Rami B IbrahimMuneer H Abidi, Lois J Ayash, Simon M Cronin, Cheryl Cadotte, Jason Mulawa, Pamela A Jacobson, Daryn W Smith, Joseph P Uberti & David J Edwards. (2008) Effect of aprepitant on intravenous tacrolimus disposition in reduced intensity hematopoietic stem cell transplantation. Journal of Oncology Pharmacy Practice 14:3, pages 113-121.
Crossref
Crossref
Angela Georgy, Jacalyn Neceskas & Susan Goodin. (2007) Antiemetic care for patients with breast cancer: Focus on drug interactions and safety concerns. American Journal of Health-System Pharmacy 64:21, pages 2227-2236.
Crossref
Crossref
Karen Nieber & Konrad Schoppmeyer. (2007)
Aprepitant, der erste therapeutisch wirksame NK
1
‐Rezeptor‐Antagonist. Prävention von Übelkeit und Erbrechen
. Pharmazie in unserer Zeit 36:5, pages 373-380.
Crossref
Crossref
F.-Z. Laalou, P. Diemunsch & C. Forestier. (2007) Nausea e vomito postoperatori. EMC - Anestesia-Rianimazione 12:3, pages 1-14.
Crossref
Crossref
F.-Z. Laalou, P. Diemunsch & C. Forestier. (2007) Náuseas y vómitos postoperatorios. EMC - Anestesia-Reanimación 33:4, pages 1-15.
Crossref
Crossref
F.-Z. Laalou, P. Diemunsch & C. Forestier. (2007) Nausées et vomissements postopératoires. EMC - Anesthésie-Réanimation 4:2, pages 1-14.
Crossref
Crossref